香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃上海復旦張江生物醫藥股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司關 於更換持續督導保薦代表人的公告》，僅供參閱。該文件及其披露內容乃根據中國法 律法規及境內相關監管要求而編制及刊發。 承董事會命 趙大君 主 席 於本公告刊發日期，董事會包括以下人士： 趙大君先生（執行董事） 薛 燕女士（執行董事） 沈 波先生（非執行董事） 余曉陽女士（非執行董事） 王宏廣先生（獨立非執行董事） 林兆榮先生（獨立非執行董事） 徐培龍先生（獨立非執行董事） 曲亞楠女士（職工董事） 中國·上海 二零二六年二月九日 * 僅供識別 上海复旦张江生物医药股份有限公司 关于更换持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容 ...

FF301 截至月份: 2026年1月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01349 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 326,000,000 | RMB | | 0.1 RMB | | 32,600,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 326,000,000 | RMB | | 0.1 RMB | | 32,600,000 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | - ...

Group 1 - Fudan Zhangjiang (01349.HK) experienced a decline of 4% during trading, with a current drop of 3.69%, priced at 3.13 HKD [1] - The trading volume reached 3.7159 million HKD [1]

Group 1 - The core viewpoint of the article indicates that Fudan Zhangjiang (01349) is experiencing a significant decline in stock price, with a drop of 4% during trading and a current price of HKD 3.13, alongside a trading volume of HKD 3.7159 million [1] - The company expects to report an unaudited net loss attributable to shareholders of approximately RMB 120 million to RMB 180 million for the fiscal year ending December 31, 2025, compared to a net profit of RMB 39.73 million in the same period of 2024 [1] - The expected net loss, excluding non-recurring items, is projected to be between RMB 140 million and RMB 200 million, while the net profit for 2024, excluding non-recurring items, was RMB 5.1452 million [1] Group 2 - The company attributes the losses to the advancement of research and development projects, with R&D expenditures rising as a percentage of operating income, amounting to approximately RMB 350 million during the period [1] - Additionally, the retail price of the product "Libao Duo" was reduced starting May 1 of the previous year, leading to a decrease in profit margins, with the product's contribution to the company's profits declining by approximately RMB 100 million year-on-year [1]

Core Viewpoint - Fudan Zhangjiang (01349) is experiencing a decline in stock price, with a reported drop of 4% during trading, currently at HKD 3.13, and a trading volume of HKD 3.7159 million. The company has announced an expected net loss attributable to shareholders of approximately RMB 120 million to RMB 180 million for the fiscal year ending December 31, 2025, compared to a net profit of RMB 39.73 million in the same period of 2024 [1][1][1] Financial Performance - The company anticipates a net loss attributable to shareholders, excluding non-recurring items, of approximately RMB 140 million to RMB 200 million, contrasting with a net profit of RMB 5.1452 million in 2024 [1][1][1] - Research and development (R&D) expenses are projected to be around RMB 350 million, contributing to the increasing proportion of R&D costs relative to operating income [1][1][1] Product Impact - The product "Libo Duo" has seen a reduction in market retail prices since May 1 of the previous year, leading to a decrease in profit margins. The contribution of this product to the company's profits has decreased by approximately RMB 100 million year-on-year [1][1][1]

Performance Forecast - The company expects a net loss attributable to shareholders for the year 2025, estimated between RMB -180 million and RMB -120 million compared to the previous year [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between RMB -200 million and RMB -140 million for 2025 [1] Previous Year Performance - In the previous year, the total profit was RMB 5.4579 million, with a net profit attributable to shareholders of RMB 39.7339 million [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 514.52 million [1] - Earnings per share for the previous year were RMB 0.04 [1] Reasons for Performance Change - The company has increased its R&D investment, which now constitutes a higher percentage of revenue, with approximately RMB 350 million invested during the reporting period [2] - Significant progress has been made in clinical trials, including the completion of patient enrollment for the FDA018 antibody-drug conjugate project ahead of schedule, with over 350 cases enrolled [1][2] - The company has adjusted its sales strategy for the liposomal doxorubicin injection product due to its inclusion in the national procurement catalog, leading to a profit contribution decrease of approximately RMB 100 million compared to the previous year [2]

Core Viewpoint - Fudan Zhangjiang Biopharmaceutical Co., Ltd. has received acceptance for its drug application for a powder oral solution of Ammonium Pentanoate Hydrochloride, aimed at visualizing malignant tissues during surgery for adult patients with high-grade malignant glioma [1] Group 1 - The drug application was accepted by the National Medical Products Administration, indicating progress in the regulatory process [1] - The clinical trial application for the drug was accepted in December 2023, with verification clinical research set to start in June 2024 [1] - The clinical research for the drug has been completed, leading to the recent acceptance of the drug registration application [1]

格隆汇1月30日丨复旦张江(688505.SH)公布，经公司财务部门初步测算，预计公司2025年年度实现归属 于母公司所有者的净利润与上年同期相比，将出现亏损，预计2025年年度实现归属于母公司所有者的净 利润为人民币-18,000万元至人民币-12,000万元。预计2025年年度实现归属于母公司所有者的扣除非经 常性损益的净利润为人民币-20,000万元至人民币-14,000万元。 ...

Group 1 - The company expects to record an unaudited net loss attributable to the parent company of approximately RMB 120 million to RMB 180 million for the fiscal year ending December 31, 2025, compared to an audited net profit of RMB 39.73 million in 2024 [1] - The company is actively advancing its R&D projects, with R&D expenditure accounting for an increasing proportion of revenue. The Phase III clinical trial for the FDA018 antibody-drug conjugate has exceeded its enrollment target, with over 350 cases enrolled [1] - The company’s subsidiary has been supporting the industrialization of antibody-drug conjugates (ADC), including technology transfer and production process validation [1] Group 2 - The company’s photodynamic drug development projects are progressing as planned, with the registration application for a powder for oral solution of Amifostine for high-grade glioma visualization accepted [2] - R&D expenditure for the reporting period was approximately RMB 350 million [2] - The company adjusted its sales strategy for the product "Li Baoduo" due to changes in market competition and the inclusion of Doxorubicin Liposome Injection in the national centralized procurement directory, leading to a profit contribution decrease of approximately RMB 100 million compared to the same period last year [2]

Summary of Key Points Core Viewpoint - Fudan Zhangjiang (01349) expects a net loss attributable to shareholders of approximately RMB 120 million to RMB 180 million for the year ending December 31, 2025, compared to a net profit of RMB 39.73 million for 2024 [1] Group Performance and R&D Progress - The company is actively advancing its R&D projects, with R&D expenditure as a percentage of revenue continuously increasing. During the reporting period, the Phase III clinical trial for the FDA018 antibody-drug conjugate (anti-Trop2 antibody conjugate SN38 project) was completed ahead of schedule, with over 350 cases enrolled [2] - The company plans to submit a listing application as soon as the data results are collected. The Phase II clinical study for the FDA022 antibody-drug conjugate (anti-HER2 antibody conjugate BB05 project) has completed enrollment, and a clinical discipline communication meeting (EOP2 meeting) with regulators was held during the reporting period [2] - The wholly-owned subsidiary, Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd., has been supporting the industrialization of the company's antibody-drug conjugate (ADC) R&D projects, including commercial-scale production technology transfer and production process validation [2] - The development of photodynamic drug projects is progressing as planned, with the application for drug registration for the oral solution of ammonium pentobarbital for intraoperative visualization in high-grade glioma having been accepted [2] - R&D investment during the reporting period was approximately RMB 350 million [2] Sales Strategy Adjustments - In 2024, the doxorubicin liposome injection was included in the national centralized procurement directory, but the company's product, Liposome Doxorubicin, was not selected. Consequently, the company adjusted its sales strategy for this product, including a gradual reduction in market retail prices starting May 1, 2025 [3] - This adjustment led to a corresponding decrease in the profit margin of Liposome Doxorubicin, with a year-on-year reduction in profit contribution of approximately RMB 100 million compared to the same period last year [3]